[Epoetin in cancer patients. Guidelines of the ASCO and the ASH for evidence-based clinical practice].
Del Mastro
Lucia
L
Oncologia Medica A, Istituto Nazionale per la Ricerca su Cancro, Genova.
D000970:Antineoplastic Agents / Q000009:adverse effects; D001803:Blood Transfusion / Q000706:statistics & numerical data; D004334:Drug Administration Schedule; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006397:Hematinics / Q000008:administration & dosage / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000628:therapy; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011788:Quality of Life; D011994:Recombinant Proteins; D015996:Survival Rate
D000970:Antineoplastic Agents; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa